Maria Ganancial
Primary Care · West Orange, NJNPI 1306299300
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,329, 8.8 times the $151 reported in 2021. Among primary care clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 303 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$579
- Merck$507
- E.r. Squibb & Sons, L.L.C.$372
- Pfizer$307
- Boehringer Ingelheim$303
- Alnylam Pharmaceuticals Inc.$264
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,631100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 55 | $579 |
| Merck | 32 | $507 |
| E.r. Squibb & Sons, L.L.C. | 24 | $372 |
| Pfizer | 26 | $307 |
| Boehringer Ingelheim | 18 | $303 |
| Alnylam Pharmaceuticals Inc. | 18 | $264 |
| Cvrx, Inc. | 11 | $223 |
| Impulse Dynamics (USA) Inc. | 9 | $194 |
| Scpharmaceuticals Inc. | 11 | $189 |
| Amgen | 11 | $166 |
| Regeneron Healthcare Solutions, Inc. | 8 | $141 |
| Altathera Pharmaceuticals LLC | 4 | $130 |
| Amarin Pharma, Inc. | 9 | $125 |
| AstraZeneca | 8 | $119 |
| Kiniksa Pharmaceuticals, Ltd. | 8 | $110 |
| Sanofi-aventis U.S. LLC | 6 | $100 |
| Bayer | 5 | $98 |
| Novo Nordisk | 5 | $81 |
| Bridgebio Pharma, Inc. | 4 | $76 |
| Abbott | 3 | $69 |
| Atricure, Inc. | 2 | $69 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $67 |
| Philips North America LLC | 2 | $55 |
| Irhythm Technologies, Inc. | 3 | $53 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Kestra Medical Technology Services, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Azurity Pharmaceuticals, Inc. | 2 | $26 |
| Edwards Lifesciences | 1 | $25 |
| Chiesi USA, Inc. | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
How this compares
$4,651 in reported general payments places this provider in the 90th percentile of 330 primary care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 121 | $149,050 |
| JardianceEmpagliflozin | 66 | $66,650 |
| EliquisApixaban | 40 | $40,200 |
| XareltoRivaroxaban | 11 | $9,432 |
| Torsemide | 107 | $2,314 |
| Metoprolol Succinate | 59 | $1,119 |
| Carvedilol | 69 | $821 |
| Spironolactone | 103 | $745 |
| Furosemide | 101 | $623 |
| Hydralazine Hcl | 23 | $446 |
| Atorvastatin Calcium | 28 | $420 |
| Rosuvastatin Calcium | 13 | $418 |
| Klor-Con M10Potassium Chloride | 12 | $372 |
| Potassium Chloride | 37 | $336 |
| Amiodarone Hcl | 29 | $280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $579 | $149,050121 claims |
| Boehringer IngelheimJardiance | $303 | $66,65066 claims |
| PfizerEliquis | $307 | $40,20040 claims |
| Johnson & JohnsonXarelto | $27 | $9,43211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 330 primary care providers in New Jersey.
Other primary care in West Orange
- Michael Zito GovertNeptune$61K
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
- Shazam BacchusNewark$7K
- Anna NievesBasking Ridge$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.